Location: Virus and Prion Research
Project Number: 5030-32000-230-068-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Jun 1, 2021
End Date: May 31, 2024
Objective:
Our goal is to validate and improve modified live-virus (MLV) PRRSV vaccine candidates that express replication-competent interferons (IFNs).
Approach:
The objective will be met using the following approaches:
1) Examine the kinetics of the incorporated IFN expression in vivo, and its effect in potentiation of antiviral immunity.
2) Implement a reverse-genetic platform to efficiently rescue and attenuate field isolates as vaccine backbones for improving vaccine efficacy and safety.
3) Optimize adjuvant regulation for better growth performance of vaccinated piglets.
